953039-25-3

Basic information

• Product Name: 6-BroMo-2-chloro-8-fluoroquinazoline
• Synonyms: 6-BroMo-2-chloro-8-fluoroquinazoline
• CAS NO: 953039-25-3
• Molecular Formula: C₈H₃BrClFN₂
• Molecular Weight: 261.4782232
• Mol File: 953039-25-3.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 308.8±35.0 °C(Predicted)
• Appearance: /
• Density: 1.836±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -1.68±0.30(Predicted)
• CAS DataBase Reference: 6-BroMo-2-chloro-8-fluoroquinazoline(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BroMo-2-chloro-8-fluoroquinazoline(953039-25-3)
• EPA Substance Registry System: 6-BroMo-2-chloro-8-fluoroquinazoline(953039-25-3)

Safety Data

• Hazardous Substances Data: 953039-25-3(Hazardous Substances Data)

Usage

General Description

6-Bromo-2-chloro-8-fluoroquinazoline is a chemical compound with molecular formula C8H4BrClF2N2. It is a quinazoline derivative that contains bromine, chlorine, and fluorine atoms. 6-BroMo-2-chloro-8-fluoroquinazoline is a potential building block for the synthesis of various organic compounds and pharmaceuticals due to its unique molecular structure and reactivity. It may be used in research and development of new drugs, as well as in the production of advanced materials and fine chemicals. Its properties and potential applications make it a valuable and versatile compound in the field of organic chemistry.

Upstream product

• 953039-26-4 2-amino-5-bromo-3-fluorobenzoic acid hydrobromide 
• 906811-50-5 (2-amino-5-bromo-3-fluorophenyl)methanol 
• 874784-14-2 2-amino-5-bromo-3-fluorobenzoic acid 
• 825-22-9 3-fluoroanthranilic acid 
• 1036756-15-6 6-bromo-8-fluoroquinazolin-2-ol 

Downstream Products

• 1036744-36-1 N-(3-(6-bromo-8-fluoroquinazolin-2-ylamino)-5-((dimethylamino)-methyl)phenyl)acetamide 

Relevant articles and documents

TREATMENT OF FIBROSIS WITH IRE1 SMALL MOLECULE INHIBITORS

Provided herein are methods of using IRE1 small molecule inhibitors in combination therapies for treating fibrosis in a subject. The IRE1 small molecule inhibitors described herein may be used in combination therapies for treating fibrosis

IRE1 SMALL MOLECULE INHIBITORS

Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.

INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR

Described herein are inhibitors of FGFR, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of tyrosine kinases.